ASND - Ascendis Pharma A/S
| Previous Close | 129.38 |
| Open | 129.39 |
| Bid | 125.65 x 800 |
| Ask | 198.00 x 800 |
| Day's Range | 126.15 - 129.12 |
| 52 Week Range | 53.21 - 131.76 |
| Volume | 138,124 |
| Avg. Volume | 376,851 |
| Market Cap | 6.06B |
| Beta (3Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.87 |
| Earnings Date | Aug 29, 2017 - Sep 4, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 159.76 |
- Insider Monkey•5 days ago
ValueAct Capital’s CBRE Recommendation Delivers 150% Gain
This is how we shared Jeff Ubben's CBRE Group Inc (NYSE:CBRE) stock pitch more than 6 years ago: "On October 2, 2012, ValueAct Capital‘s fearless leader Jeffrey Ubben made a presentation on Day 2 of the 8th Annual Value Investing Congress in New York. Entitled “Avoiding Complexity and the VAC Circle of Life”, Ubben discussed several aspects of […]
- Zacks•7 days ago
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire•12 days ago
Report: Exploring Fundamental Drivers Behind Manulife Financial, Fidelity National Financial, Heritage-Crystal Clean, Ericsson, Ascendis Pharma A/S, and Astec Industries — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•12 days ago
Shareholders Are Raving About How The Ascendis Pharma Share Price Increased 602%
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards canRead More...
- ACCESSWIRE•13 days ago
Under the Radar Cannabis Stock-THC Therapeutics, Inc.
HENDERSON, NV / ACCESSWIRE / March 6, 2019 / Cannabis research firm, ArcView, sees North American legal pot sales reaching $22 billion by 2021 and $57 billion worldwide by 2027. So, it's little surprise ...
- Benzinga•13 days ago
Ascendis Pharma Prices 4.166M ADS Offering @$122/ADS
Ascendis Pharma A/S (NASDAQ: ASND ) announced the pricing of its underwritten public offering of 4,166,667 American Depositary Shares ("ADSs"), each of which represents one ordinary share of ...
- GlobeNewswire•13 days ago
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransConTM technology to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,166,667 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $120.00 per ADS. All of the ADSs are being offered by Ascendis. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 625,000 ADSs at the public offering price, less the underwriting commissions.
- Zacks•14 days ago
Company News For Mar 5, 2019
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
- GlobeNewswire•14 days ago
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of ADSs at the public offering price, less the underwriting commissions.
- Market Realist•15 days ago
Why Ascendis Pharma Is Soaring Today
Why Ascendis Pharma Is Soaring TodayShare price movementToday, Ascendis Pharma (ASND) is trading close to $112.17, which is 61.8% higher than its previous closing price. The company’s market capitalization is $2.94 billion.Ascendis released a
- GlobeNewswire•15 days ago
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced positive top-line results from the phase 3 heiGHt Trial, a randomized, open-label, active-controlled trial that compared once-weekly TransCon Growth Hormone (hGH) to a daily growth hormone (Genotropin®) in children with pediatric growth hormone deficiency (GHD). The trial met its primary objective, demonstrating that TransCon hGH was observed to be non-inferior and, additionally, superior to the daily hGH on the primary endpoint of annualized height velocity (AHV) at 52 weeks.
- GlobeNewswire•18 days ago
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon CNP, a long-acting prodrug of C-type natriuretic peptide (CNP) in development for children with achondroplasia. Achondroplasia is the most common form of dwarfism and there are no FDA-approved therapies for this condition.
- GlobeNewswire•19 days ago
Recent Analysis Shows Intel, Gilead Sciences, Amdocs, Ascendis Pharma A/S, Hill-Rom, and Ingevity Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
- GlobeNewswire•last month
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration for initiation of PaTH Forward, a global phase 2 trial designed to evaluate the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism (HP). The trial will also evaluate a titration regimen for the complete withdrawal of standard of care (i.e., active vitamin D and calcium supplements).
- Zacks•2 months ago
All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT
Q3 2018 Ascendis Pharma A/S Earnings Call
- GlobeNewswire•2 months ago
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, today introduced Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth, at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “With the clinical validation of our three endocrinology rare disease product candidates, we have built a strong foundation to establish Ascendis as a leading rare disease company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.
- GlobeNewswire•3 months ago
Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- Insider Monkey•3 months ago
Should You Buy Ascendis Pharma A/S (ASND)?
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
Motley Fool•4 months agoAscendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript
ASND earnings call for the period ending September 30, 2018.
- GlobeNewswire•4 months ago
Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results
- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent,.
- GlobeNewswire•4 months ago
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced positive preliminary results from a phase 1 trial of TransCon CNP. Additionally, the mean resting blood pressure and heart rate were unchanged from predose levels at all time points in all cohorts.
- GlobeNewswire•4 months ago
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced the formation of VISEN Pharmaceuticals (Visen), a joint venture with an investor syndicate led by Vivo Capital, to develop, manufacture and commercialize the company’s endocrinology rare disease therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.
